The point about industry moving away from drugs that require large phase 3 studies to get approval in large populations is accurate. The vast majority of r&d th

The point about industry moving away from drugs that require large phase 3 studies to get approval in large populations is accurate. The vast majority of r&d these days goes to cancer -- increasingly genetically defined homogenous populations -- and rare disease. Smaller markets, but theoretically more tractable patient population (genetically defined population treated with genetically targeted tx) and higher pricing power